Skip to main content

Advertisement

SpringerLink
Log in

Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Subacute encephalopathy developed in four patients within one to two months after undergoing high-dose chemotherapy and bone marrow transplantation or peripheral blood progenitor (stem) cell transplantation for breast cancer, acute myeloid leukemia, and non-Hodgkin's lymphoma. None of the patients had previously known neurologic disorders, central nervous tumor or infection. Two patients presented with generalized tonic, clonic seizures, and two with confusion and lethargy. In all patients lumbar puncture and CT scans of the brain were normal, while magnetic resonance imaging (MRI) demonstrated multifocal predominantly white matter lesions. Phenytoin therapy was given to the two patients with seizures and all four patients improved without specific therapeutic intervention. Repeat MRIs became normal within three months. We report a delayed and transient encephalopathy which appears to be a unique complication of high-dose cytotoxic chemotherapy. The corresponding brain lesions may not be appreciated on CT scans, suggesting an expanded role for MRI studies in patients who develop neurologic findings while undergoing high-dose cytotoxic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Posner JB: Management of central nervous system metastasis. Semin Oncol 4: 81–91, 1977

    Google Scholar 

  2. Clouston PD, DeAngelis LM, Posner JB: The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 31: 268–271, 1992

    Google Scholar 

  3. Macdonald DR: Neurologic complications of chemotherapy. Neurologic Clin 4: 955–967, 1991

    Google Scholar 

  4. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ: Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48: 2577–2582, 1981

    Google Scholar 

  5. Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 291: 75–81, 1984

    Google Scholar 

  6. Fritsch G, Urban C: Transient encephalopathy during the late course of treatment with high-dose methotrexate. Cancer 53: 1849–1851, 1984

    Google Scholar 

  7. So NK, O'Neill BP, Frytan S: Delayed leukoencephalopathy in survivors with small cell lung cancer. Neurology 37: 1198–1201, 1987

    Google Scholar 

  8. Frytak S, Shaw JN, O'Neill BP: Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 12: 27–33, 1989

    Google Scholar 

  9. Patchell RA, White CL III, Clark AW, Beschorner WE, Santos GW: Neurologic complications of bone marrow transplantation. Neurology 35: 300–306, 1985

    Google Scholar 

  10. Burger PC, Kamenar E, Schold SC, Fay JW, Phillips GL, Herzig GP: Encephalomyelopathy following high-dose BCNU therapy. Cancer 48: 1318–1327, 1981

    Google Scholar 

  11. Davis DG, Patchell RA: Neurologic complications of bone marrow transplantation. Neurologic Clin 6: 377–387, 1988

    Google Scholar 

  12. Atkinson K, Clink H, Lawler S, Lawson DN, McElwain TJ, Thomas P, Peckham MJ, Powles R, Mann JR, Cameron AH, Arthur K: Encephalopathy following bone marrow transplantation. Eur J Cancer 13: 623–625, 1977

    Google Scholar 

  13. Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne RD, Graeb DA, Spinelli JJ, Barnett MJ, Klingemann HG, Herzig GP, Phillips GL: Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 8: 393–401, 1991

    Google Scholar 

  14. Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D, Soegiarso W, Brodsky I: High-dose carmustine, etoposide, and cisplatin, and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 10: 1682–1689, 1992

    Google Scholar 

  15. Cassileth PA, Andersen J, Lazarus HM, Colvin OM, Bennett JM, Stadtmauer EA, Kaizer H, Weiner RS, Edelstein M, Oken MM: Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 11: 314–319, 1993

    Google Scholar 

  16. Murphy CP, Harden EA, Thompson JM: Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacol 26: 30–31, 1992

    Google Scholar 

  17. Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE: Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem cell rescue: toxicity profile. J Clin Oncol 13: 323–332, 1995

    Google Scholar 

  18. Santos GW, Tutschka PJ, Bookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309: 1347–1353, 1983

    Google Scholar 

  19. Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB: Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80: 2425–2428, 1992

    Google Scholar 

  20. Marten RW, Sher C, Jacobs P, Monteaguato F: High-dose busulfan and myoclonic epilepsy [letter]. Ann Intern Med 107: 173, 1987

    Google Scholar 

  21. Tutschke PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70: 1382–1388, 1987

    Google Scholar 

  22. Walker RW, Rosenblum MK, Kempin SJ, Christian MC: Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 64: 1017–1020, 1989

    Google Scholar 

  23. Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH: Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum (II) therapy. Cancer Res 47: 1457–1460, 1987

    Google Scholar 

  24. Hande KR: Etoposide pharmacology. Semin Oncol 19: 3–9, 1992

    Google Scholar 

  25. Lazarus HM, Reed MD, Spitzer TR, Rabaa MS, Blumer JL: High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 71: 689–695, 1987

    Google Scholar 

  26. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D, Strandjord S, Giannone L, Coccia P, Weick JL, Rothman SA, Krupp KR, Lowder J, Bolwell B, Herzig GP: High-dose N, N′,N″-triethylene-thiophosphoramide (thiotepa) with autologous bone marrow. Semin Oncol 17: 2–6, 1990

    Google Scholar 

  27. Maria BL, Dennis M, Obonsawin M: Severe permanent encephalopathy in acute lymphoblastic leukemia. Can J Neurol Sci 20: 199–205, 1993

    Google Scholar 

  28. Merimsky O, Reider-Grosswasser I, Wigler N, Chaitchik S: Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand 86: 521–525, 1992

    Google Scholar 

  29. Hussain M, Wozniak AJ, Edelstein MB: Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 14: 61–75, 1993

    Google Scholar 

  30. Baker WJ, Royer GL, Weiss RB: Cytarabine and neurologic toxicity. J Clin Oncol 9: 679–693, 1992

    Google Scholar 

  31. Koenig H, Patel A: Biochemical basis for fluorouracil neurotoxicity: the role of the Krebs cycle inhibition by fluoroacetate. Arch Neurol 23: 155–160, 1970

    Google Scholar 

  32. Küpfer A, Aeschlimann C, Wermuth B, Cerny T: Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 343: 763–764, 1994

    Google Scholar 

  33. Wengs WJ, Talwar D, Bernard J: Ifosfamide-induced non-convulsive status epilepticus. Arch Neurol 50: 1104–1105, 1993

    Google Scholar 

  34. Cheson BD, Vena DA, Foss FM, Sorensen JM: Neurotoxicity of purine analogues: a review. J Clin Oncol 12: 2216–2228, 1994

    Google Scholar 

  35. Meloni G, Raucci U, Pinto RM, Spalice A, Vignetti M, Iannetti P: Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol 3: 145–148, 1992

    Google Scholar 

  36. Snider S, Bashir R, Bierman P: Neurologic complications after high-dose chemotherapy and autologous bone marrow transplantation for Hodgkin's disease. Neurology 44: 681–684, 1994

    Google Scholar 

  37. Thompson CB, Sanders JE, Flournoy N, Buckner CD, Thomas ED: The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemia. Blood 67: 195–199, 1986

    Google Scholar 

  38. Gorman DJ, Kefford R, Stuart-Harris R: Focal encephalopathy after cisplatin therapy. Med J Australia 150: 399–401, 1989

    Google Scholar 

  39. DeGroen PC, Ansamit AJ, Rakele J: Central nervous system toxicity after liver transplantation, the role of cyclosporine and cholesterol. N Engl J Med 317: 861–866, 1987

    Google Scholar 

  40. Thompson CB, Sullivan KM, June CH, Thomas ED: Association between cyclosporine neurotoxicity and hypomagnesemia [letter]. Lancet 2: 1116–1120, 1984

    Google Scholar 

  41. Johnston MV, Silverstein FS, Greenberg H, Knutsen CA, Chandler W, Phillips T, Ensminger WD: Effects of intraventricular methotrexate on cerebrospinal fluid monoamine metabolites in rhesus monkeys. Cancer Treat Rep 70: 1205–1209, 1986

    Google Scholar 

  42. Hughes RL: Cyclosporine-related central nervous system toxicity in cardiac transplantation. N Engl J Med 323: 420–421, 1990

    Google Scholar 

  43. Boon AP, Adams DH, Carey MP: Cyclosporine-associated cerebral lesions in liver transplantation [letter]. Lancet 1: 1457, 1988

    Google Scholar 

  44. Shutter LA, Green JP, Newman NJ, Hooks MA, Gordon RD: Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation. Neurology 43: 2417–2418, 1993

    Google Scholar 

  45. Stein DP, Lederman RJ, Vogt DP, Carey WD, Broughan TA: Neurological complications following liver transplantation. Ann Neurol 31: 644–649, 1992

    Google Scholar 

  46. Foreman NK, Mahmoud HH, Langston JW: 99Tcm-HMPAO SPECT and magnetic resonance studies in L-asparaginase induced cerebrovascular accident. Br J Radiol 65: 78–81, 1992

    Google Scholar 

  47. Rubin AM, Kang H: Cerebral blindness and encephalopathy with cyclosporine A toxicity. Neurology 37: 1072–1076, 1987

    Google Scholar 

  48. Vaughn DJ, Jarvik JG, Hackney D, Peters S, Stadtmauer EA: High-dose cytarabine neurotoxicity: MR findings during the acute phase. Am J Neuro Radiol 14: 1014–1016, 1993

    Google Scholar 

  49. Dirr LY, Elster AD, Donofrio PD, Smith M: Evolution of brain MRI abnormalities in limbic encephalitis. Neurology 40: 1304–1306, 1990

    Google Scholar 

  50. Hwang TL, Yung WK, Estey EH, Fields WS: Central nervous system toxicity with high-dose Ara-C. Neurology 35: 1475–1479, 1985

    Google Scholar 

  51. Hoffman DL, Howard JR Jr, Sarma R, Riggs JE: Encephalopathy, myelopathy, optic neuropathy, anosmia associated with intravenous cytosine arabinoside. Clin Neuropharmacol 16: 258–262, 1993

    Google Scholar 

  52. Byrne TN Jr, Moseley TAE, Finer MA: Myoclonic seizures following chlorambucil overdose. Ann Neurol 9: 191–196, 1981

    Google Scholar 

  53. Leff RS, Thompson JM, Daly MB, Johnson DB, Harden EA, Mercier RJ, Messerschmidt GL: Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 62: 32–35, 1988

    Google Scholar 

  54. Cohen RB, Abdallah JM, Gray JR, Foss F: Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 118: 114–116, 1993

    Google Scholar 

  55. Aoki N: Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutism. Surg Neurol 25: 279–282, 1986

    Google Scholar 

  56. Hook CC, Kimmel DW, Kvols LK: Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Annals of Neurology 31: 262–267, 1992

    Google Scholar 

  57. Feinberg WM, Swenson MR: Cerebrovascular complications of L-asparaginase therapy. Neurology 38: 127–133, 1988

    Google Scholar 

  58. Sasazaki Y, Asami K, Utsumi J: Transient subacute encephalopathy induced by high-dose methotrexate treatment in children with acute lymphoblastic leukemia and malignant lymphoma (Japanese). Gan to Kagaku Ryoho 19: 1851–1857, 1992

    Google Scholar 

  59. O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF: 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann Intern Med 108: 733–743, 1988

    Google Scholar 

  60. Major PP, Agarwal RP, Kufe DW: Deoxyformycin: neurologic toxicity. Cancer Chemother Pharmacol 5: 193–196, 1981

    Google Scholar 

  61. Sullivan KM, Storb R, Shulman HM, Shaw CM, Spence A, Beckham C, Clift RA, Buckner CD, Stewart P, Thomas ED: Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. Ann Intern Med 92: 182–189, 1982

    Google Scholar 

  62. Rowinsky EK, Cazenave L, Donehower RC: Taxol. A novel investigational antimicrotubular agent. J Natl Cancer Inst 82: 1247–1259, 1990

    Google Scholar 

  63. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Just 83: 1797–1805, 1991

    Google Scholar 

  64. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC: Sequences of taxol and cisplatin. A phase I and pharmacologic study. J Clin Oncol 9: 1692–1703, 1991

    Google Scholar 

  65. Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik P, Schaumburg HH: Taxol produces a predominantly sensory neuropathy. Neurology 39: 368–373, 1989

    Google Scholar 

  66. Capri G, Munzone E, Tarenzi E, Fulfaro F, Gianni L, Caraceni A, Martini C, Scaioli V: Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 86: 1099–1101, 1994

    Google Scholar 

  67. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC: Neurotoxicity of taxol. Monogr Natl Cancer Inst 15: 107–115, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ireland Cancer Center, Department of Medicine, University Hospital of Cleveland, Case Western Reserve University, 44106, Cleveland, Ohio, USA

    H.I. Tahsildar, R.J. Creger, B.W. Cooper & H.M. Lazarus

  2. The Ireland Cancer Center, Department of Neurology, University Hospital of Cleveland, Case Western Reserve University, 44106, Cleveland, Ohio, USA

    B.F. Remler & S.M. Snodgrass

  3. The Ireland Cancer Center, Department of Ophthalmology, University Hospital of Cleveland, Case Western Reserve University, 44106, Cleveland, Ohio, USA

    B.F. Remler

  4. The Ireland Cancer Center, Department of Radiology, University Hospital of Cleveland, Case Western Reserve University, 44106, Cleveland, Ohio, USA

    R.W. Tarr

Authors
  1. H.I. Tahsildar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B.F. Remler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R.J. Creger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B.W. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S.M. Snodgrass
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R.W. Tarr
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H.M. Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tahsildar, H., Remler, B., Creger, R. et al. Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients. J Neuro-Oncol 27, 241–250 (1996). https://doi.org/10.1007/BF00165481

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00165481

Key words

Search

Navigation